OrbiMed’s Celgene Corp CELG Stock Holding History

OrbiMed’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100,000	Closed	-$6.41M	–	154
2018 Q4	$6.41M	Buy	+100,000	New	+$7.38M	0.12%	97
2018 Q1	–	Sell	-150,000	Closed	-$15.7M	–	157
2017 Q4	$15.7M	Buy	+150,000	New	+$16.9M	0.2%	86

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

OrbiMed's CELG Position: Q2 2019 in Review

OrbiMed sold out of Celgene Corp (CELG) in Q2 2019, closing a stake of 295,000 shares — an estimated $27.8M sold.

OrbiMed first reported a position in CELG in Q2 2013 and held it in 24 quarters. The position peaked at $489M in Q3 2017. 1,288 funds tracked by Wall St. Rank hold CELG as of Q2 2019.

OrbiMed reported no remaining Celgene Corp position as of Q2 2019 after selling out during the quarter.
OrbiMed sold 295,000 Celgene Corp shares in Q2 2019, an estimated $27.8M.
OrbiMed first reported a position in Celgene Corp in Q2 2013 and held it in 24 quarters.
OrbiMed's Celgene Corp position peaked at $489M in Q3 2017.
1,288 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2019.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.